MOG (35-55)
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
MOG(35-55)是来自人髓鞘少突胶质细胞糖蛋白(MOG)的截短肽。MOG是免疫球蛋白超家族的成员,仅在中枢神经系统中表达。在人多发性硬化的小鼠和大鼠模型中,MOG负责诱导实验性自身免疫性脑脊髓炎。对髓鞘少突胶质细胞糖蛋白(MOG)的体液免疫可能参与多发性硬化(MS)的发病机制[1]。
MOG(35-55)参与诱导自身抗体产生和复发缓解型神经疾病引起的广泛斑块样脱髓鞘[2]。在HLA-DR2转基因小鼠中,髓鞘少突胶质细胞糖蛋白35-55肽诱导严重的慢性实验性自身免疫性脑脊髓炎[3]。MOG35-55具有高致脑炎性,可诱导大鼠T和B细胞的强烈反应[4]。在NOD/Lt小鼠(H-2g7)和C57BL/6小鼠(H-2b)中,单次注射MOG35-55在CFA中可诱导MS样疾病[4]。
参考文献:
De March A K, De Bouwerie M, Kolopp-Sarda M N, et al. Anti-myelin oligodendrocyte glycoprotein B-cell responses in multiple sclerosis[J]. Journal of neuroimmunology, 2003, 135(1): 117-125.
Slavin A, Ewing C, Liu J, et al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[J]. Autoimmunity, 1998, 28(2): 109-120.
Rich C, Link J M, Zamora A, et al. Myelin oligodendrocyte glycoprotein‐35–55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA‐DR2‐transgenic mice[J]. European journal of immunology, 2004, 34(5): 1251-1261.
Slavin A, Ewing C, Liu J, et al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[J]. Autoimmunity, 1998, 28(2): 109-120.
- 1. Ruihua Liu, Yan Li, et al. "OIP5-AS1 facilitates Th17 differentiation and EAE severity by targeting miR-140-5p to regulate RhoA/ROCK2 signaling pathway." Life Sci. 2021 Jan 27;119108. PMID: 33515560
- 2. Xu L, Zhang C, et al. "Rapamycin and MCC950 modified gut microbiota in experimental autoimmune encephalomyelitis mouse by brain gut axis." Life Sci. 2020;253:117747. PMID: 32376270
- 3. Xu L, Zhang C, et al. "Rapamycin combined with MCC950 to treat multiple sclerosis in experimental autoimmune encephalomyelitis." J Cell Biochem. 2018 Oct 15. PMID: 30320900
Physical Appearance | A solid |
Storage | Desiccate at -20°C |
M.Wt | 2581.97 |
Cas No. | 149635-73-4 |
Formula | C118H177N35O29S |
Solubility | ≥32.25 mg/mL in H2O; insoluble in EtOH; ≥86 mg/mL in DMSO |
Chemical Name | (S)-2-((Z)-((2S,3R)-3-amino-1,2-dihydroxy-4-phenylbutylidene)amino)-4-methylpentanoic acid compound with 2,2,2-trifluoroacetic acid (1:1) |
SDF | Download SDF |
Canonical SMILES | CC(C[C@@](/N=C(O)/[C@](O)([H])[C@@](N)([H])CC1=CC=CC=C1)([H])C(O)=O)C.FC(F)(F)C(O)=O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
细胞实验 [1]: | |
细胞系 |
脑内皮细胞 |
制备方法 |
在无菌水中的溶解度为0.50 mg/mL。若配制更高浓度的溶液,一般步骤如下:请将试管置于37 °C加热10分钟和/或将其置于超声波浴中震荡一段时间。原液于-20 °C可放置数月。 |
反应条件 |
0 ~ 50 μg/mL;48小时 |
实验结果 |
MOG (35-55) 呈剂量依赖性地显著降低蛋白浓度。给予细胞MOG (35-55) (50 μg/mL) + CFA + PTX,蛋白浓度降至CON细胞水平的37.6%。在25 μg/mL或50 μg/mL的剂量下,MOG (35-55) 乳液显著增加NADPH氧化酶和MMP-9的活性(相对于CON细胞,分别高出44.1 ~ 48.5%和2倍)。 |
动物实验 [2]: | |
动物模型 |
C57BL/6小鼠 |
给药剂量 |
50、100或150 μg;皮下注射 |
实验结果 |
与注射了150 μg MOG (35-55)的小鼠相比,在50 μg和100 μg的剂量下,MOG (35-55)在MS样疾病发展过程中引起更明显的体重减轻。于治疗后第17天,50 μg MOG (35-55)组中的3/5小鼠出现濒死症状,而100 μg和150 μg剂量组中的4/5小鼠仍然存活。然而,在这3组小鼠中,均没有观察到临床症状和疾病进展。 |
注意事项 |
请于室内测试所有化合物的溶解度。虽然化合物的实际溶解度可能与其理论值略有不同,但仍处于实验系统误差的允许范围内。 |
References: [1]. Seo JE, Hasan M, Rahaman KA, Kang MJ, Jung BH, Kwon OS. A leading role for NADPH oxidase in an in-vitro study of experimental autoimmune encephalomyelitis. Mol Immunol. 2016 Apr;72:19-27. [2]. Slavin A, Ewing C, Liu J, et al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[J]. Autoimmunity, 1998, 28(2): 109-120. |
质量控制和MSDS
- 批次: